Patent Application
20240301369
The present application claims priority of Chinese Patent Application No. 202110015598.1, filed on Jan. 6, 2021, with the title of “Polynucleotides and Expression Cassettes Comprising Coding Sequences of Toluene Dioxygenase, and Uses Thereof”, of which the content is incorporated herein in its entirety.
The present disclosure relates to the field of bioengineering and pharmaceutical and chemical production. In particular, provided is a polynucleotide comprising a coding sequence of toluene dioxygenase. Also provided are also an expression cassette, a vector and a host cell comprising the polynucleotide, as well as use thereof in the preparation of cis-cyclohexadiene o-diol compounds.
R. E. Kallio et al. found a class of aromatic ring-dihydroxylating oxygenases in aromatic hydrocarbon-degrading bacteria in the late 1960s (Gibson, D. T. et al., Biochemistry, 1968, 7, 2653). These enzymes use substrates such as benzene, toluene, naphthalene and biphenyl to achieve prokaryotic metabolism of aromatic rings through aromatic nucleus activation, ring fission and citric acid cycle intermediates. This research is important for understanding and utilizing the natural carbon cycle processes and also have applications in synthesis of unique chiral chemical intermediates. Toluene dioxygenase belongs to a class of biocatalysts which have been widely studied and is beneficial for performing important functional group transformations such as 1) aromatic cis-dihydroxylation, 2) olefin cis-dihydroxylation, 3) sulfide oxidation, 4) benzyl hydroxylation, and 5) hydrocarbon desaturation and N-dealkylation. The aromatic ring is exclusively converted to the unique chiral metabolite cis-cyclohexa-3,5-diene-1,2-diol or cis-dihydrodiol intermediates with the action of toluene oxygenase, and such enzymatic reaction provides a new pathway for the synthetic chemistry of complex molecules with chiral cis-dihydrodiols as precursors. Tomas Hudlicky et al. reported in 2018 the conversion of toluene or its analogues to cis-cyclohexadiene o-diol intermediates by a double hydroxylation reaction via enzymatic whole-cell fermentation using a toluene dioxygenase strain of E. coli JM109 (pDTG601) (Baidilov, D. et al., Angew. Chem. Int. Ed. 2018, 57, 10994-10998). They concluded from literature analysis and suggested that the natural product Tetrodotoxin could be synthesized from this intermediate by a 21-step reaction as reported by Fukuyama et al.
The DNA of the toluene dioxygenase system beared by the expression plasmid pDTG601 used by Tomas Hudlicky et al. was directly derived from the original sequence on Pseudomonas putida F1 genome, which contains not only the coding sequences of the four genes todC1 todC2 todB todA, but also the spacer sequences among the coding sequences and the combination of the four coding sequences. In general, direct use of the DNA sequence from a different species for expression in E. coli may result in unsatisfactory protein expression due to codon usage bias, species differences in promoter and ribosome recognition sites, thereby affecting the catalytic effect of the enzyme.
In an aspect, provided is a polynucleotide, comprising coding sequences of toluene dioxygenase TodC1, TodC2, TodB and TodA.
In an embodiment, the polynucleotide comprises, from 5′-end to 3′-end: (1) a first nucleotide sequence, comprising the coding sequence of TodC1, wherein the TodC1 has an amino acid sequence of SEQ ID NO: 4; (2) a second nucleotide sequence, comprising the coding sequence of TodC2, wherein the TodC2 has an amino acid sequence of SEQ ID NO: 5; (3) a third nucleotide sequence, comprising the coding sequence of TodB, wherein the TodB has an amino acid sequence of SEQ ID NO: 6; and (4) a fourth nucleotide sequence, comprising the coding sequence of TodA, wherein the TodA has an amino acid sequence of SEQ ID NO: 7; wherein the first, second, third and fourth nucleotide sequences each independently use E. coli preferred codons, and the stop codon TAA for TodB and the start codon ATG for TodA form a nested sequence TAATG.
In a specific embodiment, the polynucleotide comprises a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
In another aspect, also provided are an expression cassette or vector, comprising the polynucleotide according to the present disclosure and a host cell comprising the polynucleotide, expression cassette or vector according to the present disclosure.
In another aspect, provided is a process for preparing a toluene dioxygenase, comprising culturing the host cell according to the present disclosure under conditions suitable for the expression of the expression cassette or vector.
In Another Aspect, Provided is a Process for Preparing a Compound of Formula (2),
the process comprising,
and
preferably, R is selected from the group consisting of halogen, methyl, —CH═CH2, —CH—CHBr, —CH2CH2Br, —CH2CH2CN, —CH2CH2N3, —CH2CH2—O—C(═O)—CH3, —CH2—O—C(═O)—CH3, cyclohexyl, cyclohexenyl, and phenyl.
Accordingly, in another aspect, provided is also use of the polynucleotide, the expression cassette or vector, or the host cell according to the present disclosure for preparing a compound of formula (2).
The technical contents of the present disclosure are described with specific embodiments, and other advantages of the present disclosure can be readily appreciated by those skilled in the art according to the disclosure of the present specification. The present disclosure may also be implemented or applied with other specific embodiments. Those skilled in the art can make various modifications and changes without departing from the spirit of the present disclosure. Unless explicitly stated, the reagents and apparatus used in the following examples are conventional in the field and are commercially available. The procedures as used are also conventional, and those skilled in the art can clearly know how to conduct the experiments as described and obtain the corresponding results according to the specification.
Unless otherwise stated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the terms of protein and nucleic acid chemistry, molecular biology, cell and tissue culture, and microbiology used herein are those widely used in the fields. Moreover, definitions and explanations of relevant terms are provided below for a better understanding of the present disclosure.
As used herein, unless the context indicates otherwise, the singular form of the expression “a”, “an” or “the” encompasses the plural designation.
The ranges herein encompass the endpoints and each point value therein as well as the subranges formed by these values. For example, C1-6 encompasses C1, C2, C3, C4, C5, C6, C1-5, C2-6, C3-5, C2-4 or the like. As another example, C3-8 encompasses C3, C4, C5, C6, C7, C8, C3-7, C4-8, C5-7 or the like.
As used herein, the term “one or more” or “at least one” encompasses one, two, three, four, five, six, seven, eight, nine or more.
As used herein, a “nucleotide” comprises a deoxyribonucleotide and a ribonucleotide and a derivative thereof. A “nucleotide” is usually designated by the single letter representing the base therein: “A(a)” refers to deoxy-adenylate or adenylate, “C(c)” refers to deoxy-cytidylate or cytidylate, “G(g)” refers to deoxy-guanylate or guanylate, “U(u)” refers to uridylate, “T(t)” refers to deoxy-thymidylate.
As used herein, the term “polynucleotide” refers to a polymer of deoxyribonucleotides (DNA) or a polymer of ribonucleotides (RNA). The terms “polynucleotide sequence”, “nucleic acid sequence” and “nucleotide sequence” are used interchangeably to denote the sequence of nucleotides in a polynucleotide. A polynucleotide can be single-stranded or double-stranded. A polynucleotide can also contain a synthetic, non-natural, or modified nucleotide. A polynucleotide can contain one or more nucleotide sequences (e.g., 1, 2, 3, 4, 5, 6, 7, 8 sequences). A nucleotide sequence may comprise but be not limited to, for example, a coding sequence encoding a protein or polypeptide, a regulatory sequence regulating the expression of a coding sequence, and a restriction endonuclease cleavage site.
As used herein, a “codon” refers to a sequence of three consecutive nucleotides (also known as triplet codon) which encodes a specific amino acid in a polynucleotide. The use of codons may be biased in different species, i.e., synonymous codons (codons encoding the same amino acid) are used in different species with different frequencies. It is generally believed that protein coding sequences using preferred codons for a species can be translated with high efficiency and accuracy in the expression system of that species. The term “E. coli preferred codons” refers to codons that are used with higher frequencies in E. coli. The coding sequence contained in the polynucleotide according to the present disclosure uses E. coli preferred codons.
As used herein, the term “polypeptide” refers to a polymer containing more than two amino acids covalently linked by peptide bonds. A “protein” may contain one or more polypeptides, wherein the polypeptides interact with each other in a covalent or non-covalent manner. Unless otherwise specified, the terms “polypeptide” and “protein” may be used interchangeably.
As used herein, “isolated” means that a substance (e.g., a polynucleotide or polypeptide) is separated from the source or environment in which it exists, i.e., it is substantially free of other ingredients.
As used herein, the term “expression cassette” refers to a polynucleotide which is capable of directing the expression of a target coding sequence and comprises a target coding sequence operably linked to a regulatory sequence. The expression cassette according to the present disclosure is used to express a protein or RNA in an E. coli expression system. Regulatory sequences which can be used in the expression cassette according to the present disclosure may include, for example, a promoter, a transcription factor binding site (e.g., a ribosome binding site), an enhancer, and a transcription termination signal (e.g., a transcription terminator).
As used herein, “operably linked” means that nucleotide sequences are linked or adjacent to each other, such that the function of a nucleotide sequence is affected by another. For example, a promoter which is operably linked to a target coding sequence directs the transcription of the target coding sequence, and a ribosome binding site which is operably linked to a target coding sequence directs the translation of the target coding sequence.
As used herein, a “coding sequence” refers to a nucleotide sequence encoding a target protein (e.g., TodC1, TodC2, TodB and TodA) or polypeptide.
As used herein, the term “expression” refers to the process for producing a protein from a polynucleotide (e.g., a target coding sequence). In some embodiments, the expression vector according to the present disclosure is “inducible expression”. “Inducible expression” means that the expression of a gene needs to be achieved under specific conditions (e.g., in the presence of an inducer). For example, in some embodiments according to the present disclosure, the expression of toluene dioxygenase TodC1C2BA is induced by addition of an inducer (e.g., IPTG) to the culture medium of a recombinant strain.
As used herein, the term “promoter” refers to a nucleotide sequence comprising a sequence recognized by an RNA polymerase, which controls the expression of a coding sequence by containing a recognition sequence for an RNA polymerase and other factors required for proper transcription. A “promoter regulatory sequence” may comprise a proximal and more distal upstream and/or downstream element. A promoter regulatory sequence affects the transcription, RNA processing or stability, or translation of a coding sequence operably linked thereto. The meaning of the term “promoter” encompasses “promoter regulatory sequence”.
As used herein, an “enhancer” is a nucleotide sequence which may enhance the transcription of a target coding sequence. An enhancer may be homologous or heterologous to a promoter. It can be located upstream or downstream of the promoter sequence.
As used herein, “transformation” refers to the introduction of a polynucleotide or vector into a host cell such that the polynucleotide or vector can be expressed from the host cell. Transformation may be transient or stable. A host cell transformed with the polynucleotide, expression cassette or vector according to the present disclosure may also be referred to as a “recombinant cell”. In some embodiments, the host cell is a bacterial strain such as E. coli, and such a recombinant cell may also be referred to as a “recombinant strain”.
As used herein, the term “host cell” refers to a cell which is used to receive, maintain, replicate, or express a polynucleotide or vector. As used herein, a host cell is preferably a cell which can express the target coding sequence.
The term “toluene dioxygenase” or “TodCIC2BA” refers to the combined name of Pseudomonas putida F1 strain proteins TodC1, TodC2, TodB and TodA. The nucleotide sequences of todC1, todC2, todB and todA genes of Pseudomonas putida F1 are shown in nucleotides at positions 620-4210 of GenBank accession number: J04996.1 (SEQ ID NO: 12), which comprises spacer sequences. “TodC1” is encoded by todC1 (also known as bnzA) gene, which is also known as Benzene 1,2-dioxygenase subunit alpha, having an amino acid sequence as shown in Uniprot ID: A5W4F2 (SEQ ID NO: 4). “TodC2” is encoded by todC2 (also known as bnzB) gene, which is also known as Benzene 1,2-dioxygenase subunit beta, having an amino acid sequence as shown in Uniprot ID: A5W4F1 (SEQ ID NO: 5). “TodB” is encoded by todB gene, which is also known as Toluene 1,2-dioxygenase system ferredoxin subunit, having an amino acid sequence as shown in Uniprot ID: A5W4F0 (SEQ ID NO: 6). “TodA” is encoded by todA gene, which is also known as Toluene 1,2-dioxygenase system ferredoxin—NAD(+) reductase component, having an amino acid sequence as shown in Uniprot ID: A5W4E9 (SEQ ID NO: 7).
TodC1C2BA co-catalyzes a reaction from toluene or toluene analog (Formula (1)) to cis-cyclohexadiene o-diol compounds (Formula (2)) as shown below:
wherein R may be halogen, methyl, —CH═CH2, —CH═CHBr, —CH2CH2Br, —CH2CH2CN, —CH2CH2N3, —CH2CH2—O—C(═O)—CH3, —CH2—O—C(═O)—CH3, cyclohexyl, cyclohexenyl, or phenyl. The products obtained from different substrates catalyzed by toluene dioxygenase can be used as intermediates for the synthesis of various compounds, and relevant description can be found in e.g., Endoma, M. A., et al., Organic Process Research & Development, 2002, 6(4): 525-532.
As used herein, “toluene or toluene analog” has the structure shown in Formula (1) above.
As used herein, the term “cis-cyclohexadiene o-diol compound” has the structure shown in Formula (2) above.
As used herein, the term “substitution” indicates that one or more specific hydrogen atoms are replaced by selected group(s), provided that the normal atomic valence of the specific atom is not exceeded and that the substitution forms a stable compound. Combination of substituents and/or variables are permitted only if such combination forms a stable compound. Examples of substituents of a optionally substituted group herein may be halogen. The alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl as described herein may be optionally substituted.
As used herein, the term “halogen” refers to fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).
As used herein, “i-j” or a similar expression refers to a range covering the endpoints, each integer therein, and subranges formed by the integers therein. For example, C1-6 encompasses C1, C2, C3, C4, C5 and C6 as well as C2-C5, C3, C4 or the like.
As used herein, the term “alkyl”, either alone or in combination with other terms, refers to a branched or straight-chain saturated aliphatic hydrocarbon group having a specific number of carbon atoms. Unless otherwise indicated, “alkyl” refers to C1-6 alkyl. For example, “C1-6 alkyl” includes but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, pentyl, hexyl, or the like.
As used herein, the term “alkenyl”, either alone or in combination with other terms, refers to a branched or straight-chain unsaturated aliphatic hydrocarbon group having a specific number of carbon atoms with a carbon-carbon double bond. Unless otherwise indicated, “alkenyl” refers to C2-6 alkenyl.
As used herein, the term “cycloalkyl”, either alone or in combination with other terms, refers to a saturated aliphatic cyclic hydrocarbon group having a specific number of carbon atoms. Unless otherwise indicated, “cycloalkyl” refers to C3-8 cycloalkyl. Examples comprise but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or the like.
As used herein, the term “cycloalkenyl”, either alone or in combination with other terms, refers to an unsaturated aliphatic cyclic hydrocarbon group having a specific number of carbon atoms with a carbon-carbon double bond. Unless otherwise indicated, “cycloalkenyl” refers to C3-8 cycloalkenyl. Examples comprise but are not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl or the like.
As used herein, the term “aryl”, either alone or in combination with other terms, refers to an aromatic hydrocarbon group containing a 5- or 6-membered aromatic carbon ring. Unless otherwise indicated, “aryl” refers to C6-10 aryl. Examples comprise but are not limited to phenyl, naphthyl or the like.
The DNA recombination techniques used herein are well known in the field (see, e.g., Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y, 1989).
In an aspect, provided is a polynucleotide, comprising coding sequences of toluene dioxygenase of Pseudomonas putida F1 strain TodC1, TodC2, TodB and TodA. Preferably, the polynucleotide according to the present disclosure is isolated.
In an embodiment, the polynucleotide comprises, from 5′-end to 3′-end:
In a preferable embodiment, the first nucleotide sequence comprises nucleotides at positions 1-1350 of SEQ ID NO: 1 (see also, nucleotides at positions 1-1350 of SEQ ID NO: 2). In another preferable embodiment, the second nucleotide sequence comprises nucleotides at positions 1464-2024 of SEQ ID NO: 1 (see also, nucleotides at positions 1464-2024 of SEQ ID NO: 2). In another preferable embodiment, the third nucleotide sequence comprises nucleotides at positions 2036-2356 of SEQ ID NO: 1 (see also, nucleotides at positions 2042-2362 of SEQ ID NO: 2). In another embodiment, the fourth nucleotide sequence comprises nucleotides at positions 2359-3588 of SEQ ID NO: 1 (see also, nucleotides at positions 2365-3594 of SEQ ID NO: 2).
In some embodiments, the polynucleotide further comprises a first spacer sequence located between the first nucleotide sequence and the second nucleotide sequence, and/or a second spacer sequence located between the second nucleotide sequence and the third nucleotide sequence.
In an embodiment, the first spacer sequence comprises, from 5′-end to 3′-end, a T7 promoter, a Lac operator (LacO) and a prokaryotic ribosome binding site (rbs). In an embodiment, the T7 promoter comprises a nucleotide sequence of SEQ ID NO: 8. In an embodiment, the prokaryotic ribosome binding site is rich in AG, e.g., AAGGAG. In a specific embodiment, the prokaryotic ribosome binding site comprises a nucleotide sequence of SEQ ID NO: 9. In an embodiment, the Lac operator comprises a nucleotide sequence of SEQ ID NO: 10.
In an embodiment, the second spacer sequence comprises GTGATGTC (nucleotides at positions 2028-2035 of SEQ ID NO: 1). In a preferable embodiment, the second spacer sequence comprises an rbs sequence rich in AG, e.g., AAGGAG. In a more preferable embodiment, the second spacer sequence comprises a nucleotide sequence of SEQ ID NO: 9.
Preferably, the first spacer sequence comprises a nucleotide sequence of SEQ ID NO: 3, and/or the second spacer sequence comprises GTGATGTC (nucleotides at positions 2028-2035 of SEQ ID NO: 1) or GAAGGAGATATACC (nucleotides at positions 2028-2041 of SEQ ID NO: 2, corresponding to SEQ ID NO: 9).
In a specific embodiment, the polynucleotide comprises a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
In an embodiment, the first, second, third and fourth nucleotide sequence further each independently comprises a coding sequence of a polypeptide tag. The coding sequence of the polypeptide tag is operably linked to the coding sequence of the target polypeptide (e.g., coding sequence of TodC1, TodC2, TodB or TodA), such that the polypeptide tag and the target polypeptide are expressed as a fusion polypeptide from the same open reading frame. Examples of polypeptide tags comprise but are not limited to, glutathione S-transferase (GST), polyhistidine tag (i.e., His tag, e.g., Hiss, His6, His8, etc.), maltose binding protein (MBP), B1 domain of streptococcal G protein (GB1), thioredoxin (TRX), and small ubiquitin-related modified protein (SUMO).
In another aspect, provided is a vector, comprising the polynucleotide according to the present disclosure.
The vector may be a cloning vector or an expression vector. In a preferable embodiment, the vector is an expression vector.
In a preferable embodiment, the vector comprises the polynucleotide according to the present disclosure in the form of an expression cassette, and such a vector can be an expression vector. Accordingly, in another aspect, provided is an expression cassette, comprising the polynucleotide according to the present disclosure and a regulatory sequence. The regulatory sequence is operably linked to the polynucleotide according to the present disclosure and directs the expression of the protein of interest (e.g., toluene dioxygenase TodC1, TodC2, TodB and TodA). Regulatory sequences suitable for the expression cassette may include but be not limited to a promoter, a transcriptional enhancer, a translational enhancer, a prokaryotic ribosome binding site, a regulatory element of Lac operon, a transcription terminator and a combination thereof. In a preferable embodiment, the regulatory sequence is a promoter, a prokaryotic ribosome binding site, a transcription terminator or a combination thereof. In a more preferable embodiment, the regulatory sequence is a promoter, a regulatory element of Lac operon, a prokaryotic ribosome binding site, a transcription terminator or a combination thereof.
A promoter is usually located upstream of the coding sequence of the protein of interest. A preferable promoter which can be used according to the present disclosure is T7 promoter. An exemplary nucleotide sequence of T7 promoter is shown in SEQ ID NO: 8. In an embodiment, the regulatory sequence comprises a second promoter, which is located upstream of the polynucleotide according to the present disclosure. In a specific embodiment, the second promoter is a T7 promoter. In a specific embodiment, the T7 promoter comprises a nucleotide sequence of SEQ ID NO: 8.
A prokaryotic ribosome binding site is usually located between the promoter and the coding sequence of the protein of interest. Preferably, the prokaryotic ribosome binding site is located 5-10 bases upstream of the start codon. The prokaryotic ribosome binding site may be for example, a Shine-Dalgarno sequence. Preferably, the prokaryotic ribosome binding site is rich in AG. An exemplary nucleotide sequence of prokaryotic ribosome binding site is shown in SEQ ID NO: 9. In an embodiment, the regulatory sequence further comprises a second prokaryotic ribosome binding site, which is located between the second promoter as described above and the polynucleotide according to the present disclosure. In a specific embodiment, the second prokaryotic ribosome binding site comprises a nucleotide sequence of SEQ ID NO: 9.
The regulatory element of the Lac operon may be, for example, the promoter sequences and coding sequence of Lac operator (Lac operator, LacO), and Lac inhibitor (LacI). In a preferable embodiment, the expression cassette according to the present disclosure comprises a Lac operator, which is located between the promoter and the coding sequence of the protein of interest, and the promoter sequence and coding sequence of the Lac inhibitor are present in another expression cassette of the same vector. In other embodiments, the expression cassette according to the present disclosure comprises a Lac operator, which is located between the promoter and the coding sequence of the protein of interest, and the promoter sequence and coding sequence of the Lac inhibitor are present in a second vector. An exemplary nucleotide sequence of Lac operator is shown in SEQ ID NO: 10. In a further embodiment, the regulatory sequence further comprises a second Lac operator, which is located between the second promoter and the second prokaryotic ribosome binding site as described above. In a specific embodiment, the second Lac operator comprises a nucleotide sequence of SEQ ID NO: 10.
In a specific embodiment, the expression cassette or vector comprises, from 5′-end to 3′-end: (1) a second promoter; and (2) the polynucleotide according to the present disclosure. In a specific embodiment, the second promoter is a T7 promoter. In a specific embodiment, the T7 promoter comprises a nucleotide sequence of SEQ ID NO: 8.
In a specific embodiment, the expression cassette or vector comprises, from 5′-end to 3′-end: (1) a second promoter; (2) a second prokaryotic ribosome binding site; and (3) the polynucleotide according to the present disclosure. In a specific embodiment, the second promoter is a T7 promoter. In an embodiment, the T7 promoter comprises a nucleotide sequence of SEQ ID NO: 8. In a preferable embodiment, the second prokaryotic ribosome binding site sequence is rich in AG. In a specific embodiment, the second prokaryotic ribosome binding site comprises a nucleotide sequence of SEQ ID NO: 9.
In another specific embodiment, the expression cassette or vector comprises, from 5′-end to 3′-end: (1) a second promoter; (2) a second Lac operator; (3) a second prokaryotic ribosome binding site; and (4) the polynucleotide according to the present disclosure. In a specific embodiment, the second promoter is a T7 promoter. In a specific embodiment, the T7 promoter comprises a nucleotide sequence of SEQ ID NO: 8. In a preferable embodiment, the second prokaryotic ribosome binding site sequence is rich in AG, for example AAGGAG. In a specific embodiment, the second prokaryotic ribosome binding site comprises a nucleotide sequence of SEQ ID NO: 9. In another specific embodiment, the second Lac operator comprises a nucleotide sequence of SEQ ID NO: 10.
In the above-mentioned embodiments, the expression cassette or vector may further comprise a transcription terminator. The transcription terminator may be located downstream of the coding sequence of the protein of interest. Selection of the transcription terminator is coordinated with that of the promoter in the vector and the RNA polymerase contained in the host system. In an embodiment where the promoter is a T7 promoter and the transcription terminator may be a T7 transcription terminator. An exemplary nucleotide sequence of T7 transcription terminator is shown in SEQ ID NO: 11. In an embodiment, the second promoter is a T7 promoter and the transcription terminator is a T7 transcription terminator. In a specific embodiment, the T7 transcription terminator comprise a nucleotide sequence of SEQ ID NO: 11.
In an embodiment, the expression cassette or vector comprises, from 5′-end to 3′-end:
In a specific embodiment, the expression cassette or vector comprises, from 5′-end to 3′-end: (1) a second T7 promoter (preferably having a nucleotide sequence of SEQ ID NO: 8); (2) a second Lac operator (preferably having a nucleotide sequence of SEQ ID NO: 10); (3) a second prokaryotic ribosome binding site (preferably having a nucleotide sequence of SEQ ID NO: 9); (4) the polynucleotide according to the present disclosure (preferably having a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2); and (5) a T7 transcription terminator (preferably having a nucleotide sequence of SEQ ID NO: 11).
The vector may also comprise a replication origin (e.g., pUC origin, pBR322 origin or pMB1 origin) and an antibiotic resistance gene (e.g., kanamycin resistance gene, carbenicillin resistance gene or ampicillin resistance gene) expression cassettes. The antibiotic resistance gene expression cassette may typically comprise the promoter and the coding sequence of the antibiotic resistance gene. The replication origin and antibiotic resistance gene expression cassettes which can be used in the present disclosure may be those known to those of skill in the art, such as those used in commercially available vectors.
The polynucleotide according to the present disclosure may be cloned into a commercially available vector. The vector that can be used in the present disclosure is preferably a plasmid vector. Preferably, a commercially available plasmid vector may comprise a T7 promoter, a prokaryotic ribosome binding site and a T7 transcription terminator, which may direct the expression of the polynucleotide according to the present disclosure in a host cell expressing T7 polymerase. More preferably, a commercially available plasmid vector may further comprise the regulatory element of Lac operon. Such a vector may be, for example, pET series vector (Novagen). In some embodiments, the vector according to the present disclosure may be derived from a vector selected from the group consisting of pET-3a-d, pET-9a-d(+), pET-11a-d, pET-14b, pET-21a-d(+), pET-23a-d(+), pET-24a-d(+), pET-30a-c(+), pET-28a-c(+), pET31b(+), pET32a-c(+), p33b, pET-41a-c(+), pET-42a-c(+). A phage vector and phagemid vector are also contemplated. In a specific embodiment, the vector according to the present disclosure is derived from pET-24a(+) and comprises a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
In another aspect, provided is a host cell, comprising the polynucleotide, the expression cassette or vector according to the present disclosure.
The expression cassette or vector according to the present disclosure may be introduced into a suitable host cell for the expression of toluene dioxygenase. Host cells which can be used in the present disclosure are commercially available. Preferably, the host cell is E. coli. For a host cell for protein expression, E. coli is more preferable. More preferably, the chromosome of the E. coli is integrated with a λ phage DE3 region (which contains the coding sequence of the T7 phage RNA polymerase), enabling E. coli to express the T7 RNA polymerase. More preferably, the expression of T7 RNA polymerase in E. coli is inducible. For example, the expression of T7 RNA polymerase in E. coli may be induced with IPTG, by placing the T7 RNA polymerase under the control of Lac operon. In an embodiment, the host cell is selected from the group consisting of E. coli BL21(DE3), BL21-Gold (DE3), BL21-Gold (DE3)pLysS, Rosetta (DE3), Origami™ 2 (DE3), OrigamiB (DE3), Origami™ B (DE3)pLysS, Rosetta-gami B (DE3) and Lemo21 (DE3). In a specific embodiment, the host cell is E. coli BL21(DE3), which is transformed with an expression vector of toluene dioxygenase, wherein the expression vector of toluene dioxygenase is derived from pET-24a(+) and comprises a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
The vector according to the present disclosure may be introduced into a host cell using conventional transformation techniques known in the art. Such techniques include but are not limited to calcium phosphate co-precipitation, calcium chloride co-precipitation, heat shock, recombinant phage transduction, electroporation, triparental hybridization (see, for example Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y, 1989).
In another aspect, provided is a process for preparing a toluene dioxygenase, comprising culturing the host cell according to the present disclosure under conditions suitable for the expression of the expression cassette or vector according to the present disclosure. In some embodiments, the process further comprises lysing the host cell expressing the toluene dioxygenase to give a lysate comprising the toluene dioxygenase. In another embodiment, the process further comprises purifying the toluene dioxygenase.
In a specific embodiment, the host cell is E. coli BL21(DE3) transformed with the vector according to the present disclosure.
In a specific embodiment, culturing the host cell under conditions suitable for the expression of the expression cassette or vector comprises:
In a specific embodiment, the inorganic salt medium comprises 6-10 g/L KH2PO4•3H2O, 11-15 g/L K2HPO4, 1-3 g/L (NH4)2SO4, 1-3 g/L MgSO4•7H2O, 1-3 g/L trisodium citrate dihydrate, 2-5 g/L soybean peptone, 5-10 g/L glucose monohydrate, 0.1-1 g/L GPE, 10-20 mL/L trace element solution, which comprises: 10-20 g/L citric acid monohydrate, 1-5 g/L FeCl3•6H2O, 0.5-1 g/L ZnSO4•7H2O, 0.1-0.5 g/L CoCl2•6H2O, 0.1-0.5 g/L CuSO4•5H2O, 0.1-0.5 g/L H3BO3, 1-5 g/L MnSO4•H2O and 1-5 g/L CaCl2•2H2O.
Processes for Preparing Cyclohexadiene o-Diol Compounds
In another aspect, provided is a process for preparing a compound of formula (2),
the process comprising,
and
wherein R is selected from the group consisting of halogen, —C1-6 alkyl, —C2-6 alkenyl, —C1-6 alkyl-CN, —C1-6 alkyl-O—C(═O)—C1-6 alkyl, —C3-8 cycloalkyl, —C3-8 cycloalkenyl, and —C6-10 aryl, wherein the C1-6 alkyl, —C2-6 alkenyl, —C1-6 alkyl-CN, —C1-6 alkyl-O—C(═O)—C1-6 alkyl, —C3-8cycloalkyl, —C3-8 cycloalkenyl, and —C6-10 aryl are optionally substituted with one or more halogen;
preferably, R is selected from the group consisting of halogen, methyl, —CH—CH2, —CH═CHBr, —CH2CH2Br, —CH2CH2CN, —CH2CH2N3, —CH2CH2—O—C(═O)—CH3, —CH2—O—C(═O)—CH3, cyclohexyl, cyclohexenyl and phenyl.
In a specific embodiment, R is methyl, the compound of formula (1) is toluene and the compound of formula (2) is cis-(1S,2R)-3-methyl-3,5-cyclohexadiene-1,2-diol. In a specific embodiment, R is I, the compound of formula (1) is iodobenzene and the compound of formula (2) is cis-(1S,2R)-3-Iodo-3,5-cyclohexadiene-1,2-diol. In another specific embodiment, R is —CH2—O—C(═O)—CH3, the compound of formula (1) is benzyl acetate and the compound of formula (2) is cis-(1S,2R)-3-acetoxymethyl-3,5-cyclohexadiene-1,2-diol.
In a specific embodiment, the host cell is E. coli BL21(DE3), which is transformed with an expression vector of toluene dioxygenase, wherein the expression vector of toluene dioxygenase is derived from pET-24a(+) and comprises a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
In a specific embodiment, step (1) of the above process comprises,
(1-1) culturing E. coli BL21(DE3) transformed with the vector according to the present disclosure using an inorganic salt medium under conditions of temperature at about 30-37° C., pH of about 6.8-7.3 and dissolved oxygen of ≥20%;
(1-2) adding 66% glucose solution at a rate of 12-18 mL/hr/L for replenishment upon sudden rise in dissolved oxygen; and
(1-3) at OD600 of about 30-50, lowering the temperature to 20-30° C. and adding isopropyl-β-D-thiogalactoside (IPTG) at a final concentration of 0.1-1 mM for inducible expression. In an embodiment, step (2) of the above process comprises, after initiation of IPTG-inducible expression, adding the compound of formula (1) to the fermenter in a flow-through manner, reducing the 66% glucose replenishment rate to 6-12 mL/hr/L until the end of fermentation. In an embodiment, step (2) further comprises detecting the product concentration using HPLC and stopping the reaction when the product concentration is no longer increasing.
In an embodiment, step (3) of the above process comprises, (3-1) collecting the supernatant of the fermentation broth by centrifugation; and (3-2) obtaining the product of the compound of formula (2) from the fermentation supernatant.
In a specific embodiment, step (3) comprises,
(3-1) Adjusting pH of the fermentation broth to 7.5-9.0 and collecting the fermentation broth supernatant by centrifugation;
(3-2) Adding dichloromethane or ethyl acetate to the supernatant of the fermentation broth from step (3-1) and extracting to give an aqueous phase and an organic phase containing the product; optionally, adding dichloromethane or ethyl acetate to the aqueous phase and extracting again to combine the organic phases;
(3-3) Concentrating the organic phase of step (3-2) under reduced pressure, adding appropriate amount of anhydrous sodium sulfate, and filtering to give the crude product;
(3-4) Continuing concentrating the crude product of step (3-3), adding petroleum ether for slurrying until the oil becomes solid; and (3-5) adding methyl tert-butyl ether to the solid from step (3-4) for slurrying, and drying at 30-50° C. under reduced pressure to give the product of the compound of formula (2).
In a specific embodiment, the compound of formula (1) is benzyl acetate, the compound of formula (2) is cis-(1S,2R)-3-acetoxymethyl-3,5-cyclohexadiene-1,2-diol.
Accordingly, in another aspect, provided is use of the polynucleotide, the expression cassette or vector, or the host cell according to the present disclosure for preparing a compound of formula (2).
The compound of formula (2) (particularly cis-(1S,2R)-3-acetoxymethyl-3,5-cyclohexadiene-1,2-diol and cis-(1S,2R)-3-Iodo-3,5-cyclohexadiene-1,2-diol) may be used as intermediates to prepare Tetrodotoxin (see, e.g., Baidilov, D. et al., Angew. Chem. Int. Ed. 2018, 57, 10994-10998). Accordingly, in another aspect, provided is also use of the polynucleotide, the expression cassette or vector, or the host cell according to the present disclosure for preparing Tetrodotoxin.
Provided is a polynucleotide, comprising coding sequences of toluene dioxygenase of Pseudomonas putida F1 strain (i.e., TodC1, TodC2, TodB and TodA). Provided is also an expression cassette and vector, comprising the polynucleotide according to the present disclosure. The polynucleotide, the expression cassette and vector according to the present disclosure are suitable for expressing the toluene dioxygenase in E. coli.
The expression system in the prior art (e.g., Baidilov, D. et al., Angew. Chem. Int. Ed. 2018, 57, 10994-10998) is pDTG601 vector and JM109 strain. The pDTG601 vector uses tac promoter, and the spacer sequences between the sequences encoding TodC1C2BA are directly derived from the genome of Pseudomonas putida F1 strain (GenBank accession number: J04996.1, nucleotides at positions 620-4210; sequence shown in SEQ ID NO: 12).
In contrast, the expression cassette or vector according to the present disclosure uses strong T7 promoter, E. coli preferred codons are used in the coding sequences of TodC1C2BA, and the spacer sequences between the coding sequences are replaced with a sequence containing T7 promoter and/or E. coli ribosome binding site. Constructed with the polynucleotide according to the present disclosure, the vector and recombinant strain are able to achieve the beneficial effect of efficient expression of toluene dioxygenase system in E. coli.
The polynucleotide, expression cassette, vector and re recombinant strain may be used to prepare cyclohexadiene o-diol compounds (e.g., cis-(1S,2R)-3-acetoxymethyl-3,5-cyclohexadiene-1,2-diol), with the product concentration of 2.1-7.8 g/L, e.g., 2.1, 2.3 and 7.8 g/L, which is higher than that of prior art as 1.7-2.1 g/L.
The expression system according to the present disclosure is capable of continuous production with high efficiency on a large scale, providing a novel option for the total synthesis on a large scale of complex molecules such as Tetrodotoxin with chiral cis-dihydrodiol compounds as precursors, making it possible to conduct clinical trials of Tetrodotoxin as a regulatory drug candidate, and being the foundation for the manufacture of Tetrodotoxin as a c-GMP active pharmaceutical ingredient for human analgesic and detoxification drug candidates.
Unless otherwise indicated, the instruments and reagents used herein are commercially available.
LB liquid medium: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl.
TB liquid medium: 12 g/L tryptone, 24 g/L yeast extract, 4 mL/L glycerin, 2.3 g/L KH2PO4, 16.4 g/L K2HPO4•3H2O.
Trace element solution: 14.4 g/L citric acid monohydrate, 3.0 g/L FeCl3•6H2O, 0.9 g/L ZnSO4•7H2O, 0.2 g/L CoCl2•6H2O, 0.2 g/L CuSO4•5H2O, 0.2 g/L H3BO3, 1.1 g/L MnSO4•H2O, 1.2 g/L CaCl2•2H2O.
Inorganic salt medium: 7.9 g/L KH2PO4.3H2O, 13.0 g/L K2HPO4, 2.1 g/L (NH4)2SO4, 1.7 g/L MgSO4•7H2O, 1.1 g/L trisodium citrate dihydrate, 2.5 g/L soybean peptone, 7.5 g/L glucose monohydrate, 0.5 g/L GPE, 10 mL/L trace element solution.
66% glucose solution: 660 g/L glucose monohydrate.
Based on the TodCIC2BA encoding gene in Pseudomonas putida F1 strain (GenBank accession number: J04996.1, nucleotides at positions 620-4210 (SEQ ID NO: 12)), two polynucleotides suitable for expressing TodC1/TodC2/TodB/TodA proteins in E. coli system were designed, having the nucleotide sequences as shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
Compared to the nucleotide sequence of SEQ ID NO: 12, the polynucleotide according to the present disclosure has the following features:
The polynucleotides containing the coding sequence of toluene dioxygenase (SEQ ID NO: 1 and SEQ ID NO: 2) were synthesized by GENEWIZ Suzhou Biotechnology Co. Ltd with a nucleotide sequence cat and the cleavage site ggatcc for the restriction endonuclease BamHI added at the 5′-end and 3′-end, respectively and then were cloned into the Ndel-BamHI sites of pET-24a(+) (Novagen) to give the expression plasmids pET-24a-SEQ1 and pET-24a-SEQ2, respectively (
The polynucleotide with a sequence as shown in SEQ ID NO: 13 was designed. The coding sequences of TodC1, TodC2, TodB and TodA in SEQ ID NO: 13 use E. coli preferred codons and are identical to the corresponding sequences in SEQ ID NO: 1 and SEQ ID NO: 2, but the two spacer sequences S1 and S2 are consistent with the corresponding sequences in SEQ ID NO: 12. As described above, the expression plasmids pET-24a-SEQ12 and pET-24a-SEQ13 were constructed based on SEQ ID NO: 12 and SEQ ID NO: 13, respectively. Recombinant strains BL21(DE3)(pET-24a-SEQ12) and BL21(DE3)(pET-24a-SEQ13) were prepared by transforming pET-24a-SEQ12 and pET-24a-SEQ13 into BL21(DE3).
Single colonies of the recombinant strains were seeded in the LB liquid medium (containing 50 μg/mL kanamycin) and grown for 16 hr at 37° C. to obtain the seed solution. The seed solution was inoculated into the LB liquid medium (containing 50 μg/mL kanamycin) at 1% and incubated in the shaker at 37° C. until OD600=0.5-1.0. The shaker temperature was lowered to 25° C. and isopropyl-β-D-thiogalactoside (IPTG) at a final concentration of 0.1 mM was added for induction of expression. The shaker culture was continued until 24 hr. The fermentation broth was centrifuged at 4° C. for 15 min at 8000 rpm to collect the bacteria. The bacteria were washed once with the binding buffer (50 mM Tris-HCl (pH 8.0), 0.5 M NaCl) and resuspended in the binding buffer (a small amount of bacteria solution was kept as whole cell (T) sample), and the suspension was sonicated in an ice-water bath. The lysed bacterial was centrifuged at 4° C., 12000 rpm for 20 min. The lysate supernatant (S) and precipitate (P) were collected respectively for protein sample preparation and subjected to SDS-PAGE protein gel electrophoresis analysis.
As shown in
In strain BL21(DE3)(pET-24a-SEQ12), only TodC1 was clearly expressed. Comparing samples 12T, 12S and 12P in
In strains BL21(DE3)(pET-24a-SEQ1) and BL21(DE3)(pET-24a-SEQ2), TodC1 and TodC2 proteins were clearly soluble, and there was no significant difference between the two strains in terms of protein expression levels. Compared with BL21(DE3)(pET-24a-SEQ13), the soluble expression of TodC2 protein was significantly increased in BL21(DE3)(pET-24a-SEQ1) and BL21(DE3)(pET-24a-SEQ2), indicating that the design of the first spacer sequence was very important for the expression of downstream proteins (at least for TodC2).
In addition, there were no bands for significant expression of TodB and TodA proteins in the four strains, which may be due to their coding sequences being located at more downstream positions in the expression cassette.
Single colonies of strain BL21(DE3)(pET-24a-SEQ1) were seeded in the TB liquid medium (containing 50 μg/mL kanamycin) and grown for 16 hr at 37° C. to give the seed solution. The seed solution was inoculated into a fermenter pre-filled with 25 L of inorganic salt medium (containing 50 μg/mL kanamycin) at 1% and incubated at 37° C. The pH was controlled at about 7.0 with aqueous ammonia, and the dissolved oxygen was controlled at ≥20% by adjusting the tank pressure, rotation speed and aeration. At about the fourth to fifth hr, the dissolved oxygen suddenly increased (indicating that the original carbon source was depleted), and the 66% glucose solution replenishment was initiated, with the replenishment rate set at 15 mL/hr/L. At about the eighth to ninth hr, when the OD600 was about 40, the temperature was lowered to 25° C. and IPTG at a final concentration of 0.1 mM was added for induction of expression. At about the nineteenth to twenty-second hr, 90 g of the substrate benzyl acetate was added to the fermenter in a uniform flow rate over 3 hr, and the 66% glucose replenishment rate was reduced to 12 mL/hr/L until the end of fermentation. The conversion was stopped when the product no longer increased as detected by HPLC, and the product concentration was about 2.1 g/L. The HPLC chromatograph of the conversion process is shown in
The HPLC method: Agilent Liquid Chromatograph 1260 system; column, Agilent ZORBAX Eclipse XDB-C18 5 μm (4.6 mm×250 mm); mobile phase: (A: methanol, B: water); flow rate: 1 mL/min; detection wavelength: 270 nm; column temperature: 30° C.; injection volume: 10 μL. HPLC gradient conditions:
Sample preparation: The fermentation broth was centrifuged at 12000 rpm for 10 min, the supernatant was diluted 5-10 times with methanol, mixed and centrifuged at 12000 rpm for 10 min, and the supernatant was loaded in the liquid phase.
After the fermentation transformation was completed, the pH of the fermentation broth was adjusted to 8.0 with 5 N NaOH. The fermentation broth supernatant was collected by centrifugation at 8000 rpm for 10 min, as about 30 L. 60 L of dichloromethane was added to the fermentation broth supernatant, which was stirred, and the organic phase was collected after standing for layering. 60 L of dichloromethane was added to the upper aqueous phase for extraction again and the organic phases were combined. The organic phase was concentrated to 1 L at 40° C. under reduced pressure, and a brown clear solution was obtained by adding appropriate amount of anhydrous sodium sulfate and filtration. The clear solution was further concentrated and dried, and then slurried with the addition of petroleum ether until the oil became solid. The supernatant was discarded. The solid was then slurried with methyl tert-butyl ether and dried at 30° C. under reduced pressure to give 45.3 g of product as off-white solid. The NMR spectrum (Bruker 400 MHZ) of the product cis-(1S,2R)-3-acetoxymethyl-3,5-cyclohexadiene-1,2-diol (CAS:131043-51-1) was shown in
Single colonies of strain BL21(DE3)(pET-24a-SEQ2) were seeded in the TB liquid medium (containing 50 μg/mL kanamycin) and grown for 16 hr at 37° C. to give the seed solution. The seed solution was inoculated into a fermenter pre-filled with 25 L of inorganic salt medium (containing 50 μg/mL kanamycin) at 1% and incubated at 37° C. The pH was controlled at about 7.0 with aqueous ammonia, and the dissolved oxygen was controlled at ≥20% by adjusting the tank pressure, rotation speed and aeration. At about the fourth to fifth hr, the dissolved oxygen suddenly increased (indicating that the original carbon source was depleted), and the 66% glucose solution replenishment was initiated, with the replenishment rate set at 15 mL/hr/L. At about the eighth to ninth hr, when the OD600 was about 40, the temperature was lowered to 25° C. and IPTG at a final concentration of 0.1 mM was added for induction of expression. At about the nineteenth to twenty-second hr, 90 g of the substrate benzyl acetate was added to the fermenter in a uniform flow rate over 3 hr, and the 66% glucose replenishment rate was reduced to 12 mL/hr/L until the end of fermentation. The conversion was stopped when the product no longer increased as detected by HPLC, and the product concentration was about 2.3 g/L.
After the fermentation transformation was completed, the pH of the fermentation broth was adjusted to 8.0 with 5 N NaOH. The fermentation broth supernatant was collected by centrifugation at 8000 rpm for 10 min, as about 30 L. 30 L of ethyl acetate was added to the fermentation broth supernatant, which was stirred, and the organic phase was collected after standing for layering. 30 L of ethyl acetate was added to the upper aqueous phase for extraction again and the organic phases were combined. The organic phase was concentrated to 1 L at 40° C. under reduced pressure, and a brown clear solution was obtained by adding appropriate amount of anhydrous sodium sulfate and filtration. The clear solution was further concentrated and dried, and then slurried with the addition of petroleum ether until the oil became solid. The supernatant was discarded. The solid was then slurried with methyl tert-butyl ether and dried at 30° C. under reduced pressure to give about 50 g of product as off-white solid.
Single colonies of strain BL21(DE3)(pET-24a-SEQ12) were seeded in the TB liquid medium (containing 50 μg/mL kanamycin) and grown for 16 hr at 37° C. to give the seed solution. The seed solution was inoculated into a fermenter pre-filled with 25 L of inorganic salt medium (containing 50 μg/mL kanamycin) at 1% and incubated at 37° C. The pH was controlled at about 7.0 with aqueous ammonia, and the dissolved oxygen was controlled at ≥20% by adjusting the tank pressure, rotation speed and aeration. At about the fourth to fifth hr, the dissolved oxygen suddenly increased (indicating that the original carbon source was depleted), and the 66% glucose solution replenishment was initiated, with the replenishment rate set at 15 mL/hr/L. At about the eighth to ninth hr, when the OD600 was about 40, the temperature was lowered to 25° C. and IPTG at a final concentration of 0.1 mM was added for induction of expression. At about the nineteenth to twenty-second hr, 90 g of the substrate benzyl acetate was added to the fermenter in a uniform flow rate over 3 hr, and the 66% glucose replenishment rate was reduced to 12 mL/hr/L until the end of fermentation. The concentration of the product was about 0.7 g/L as detected by HPLC, with a large amount of substrate remained.
The strain BL21(DE3)(pET-24a-SEQ13) was subjected to biotransformation as described above, and the product concentration was about 0.9 g/L as detected by HPLC, with a large amount of substrate remained.
Single colonies of strain BL21(DE3)(pET-24a-SEQ2) were seeded in the TB liquid medium (containing 50 μg/mL kanamycin) and grown for 16 hr at 37° C. to give the seed solution. The seed solution was inoculated into a fermenter pre-filled with 50 L of inorganic salt medium (containing 50 μg/mL kanamycin) at 1% and incubated at 37° C. The pH was controlled at about 7.0 with aqueous ammonia, and the dissolved oxygen was controlled at ≥20% by adjusting the tank pressure, rotation speed and aeration. At about the fourth to fifth hr, the dissolved oxygen suddenly increased (indicating that the original carbon source was depleted), and the 66% glucose solution replenishment was initiated, with the replenishment rate set at 15 mL/hr/L. At about the eighth to ninth hr, when the OD600 was about 40, the temperature was lowered to 25° C. and IPTG at a final concentration of 0.1 mM was added for induction of expression. At about the fifteenth to twenty-second hr, 700 g of the substrate benzyl acetate was added to the fermenter in a uniform flow rate over 7 hr, and the 66% glucose replenishment rate was reduced to 12 mL/hr/L until the end of fermentation. The conversion was stopped when the product no longer increased as detected by HPLC, and the concentration of the product was about 7.8 g/L.
After the fermentation transformation was completed, the pH of the fermentation broth was adjusted to 8.0 with 5 N NaOH. The supernatant of the fermentation broth was collected by centrifugation in a continuous flow tube centrifuge, as about 60 L. 60 L of ethyl acetate was added to the fermentation broth supernatant, which was stirred, and the organic phase was collected after standing for layering. 60 L of ethyl acetate was added to the upper aqueous phase for extraction again and the organic phases were combined. The organic phase was concentrated to 10 L at 40° C. under reduced pressure, and a brown clear solution was obtained by adding appropriate amount of anhydrous sodium sulfate and filtration. The clear solution was further concentrated and dried, and then slurried with the addition of petroleum ether until the oil became solid. The supernatant was discarded. The solid was then slurried with methyl tert-butyl ether and dried at 30° C. under reduced pressure to give about 351 g of product as off-white solid.
Although the present invention has been disclosed as above with detailed embodiments, they are not intended to limit the same. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of the invention. Accordingly, the scope of protection of the invention should be defined by the claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202110015598.1 | Jan 2021 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2022/070188 | 1/5/2022 | WO |
